Literature DB >> 35535204

A pyroptosis-related prognosis model to predict survival in colorectal cancer patients.

Meiyan Chen1, Jingyi Zhang1, Xiaoyan Lin2, Xiaosan Zhu1, Tao Xie3.   

Abstract

Pyroptosis is a recently-identified pathway of host cell death that is stimulated by a range of microbial infections. Emerging evidence indicates pyroptosis plays crucial roles in tumor growth, disease progression, and migration of different cancer cells. However, the clinical significance of pyroptosis in tumor behavior prognosis, as well as the underlying mechanism in different cancers remains elusive. Here, by evaluating the expression level of pyroptosis genes in colorectal cancer (CRC) patients from the TCGA cohort and GEO cohort (GSE39582), we identified pyroptosis-related DEGs and then built a 13-gene risk model by applying the LASSO Cox regression algorithm. Furthermore, functional analysis using GSEA and GSEV revealed that our prognostic model may function through regulating immune responses and tumor biogenesis pathways. Significant infiltration of activated immune cells (e.g. cytotoxic T cells) was observed in the low risk score group. The selected gene set was further validated in the GEO cohort. Time-dependent ROC curves confirmed that our risk score model is robust in predicting 1, 3 and 5-year overall survival in CRC patients. Overall, we have identified a pyroptosis-related gene signature that consists of 13 genes, which serves as a potent indicator of CRC prognosis. Thus, our model provides insights in how to make better clinical decision in the future. IJCEP
Copyright © 2022.

Entities:  

Keywords:  Pyroptosis; colorectal cancer; gene signature; prognosis

Year:  2022        PMID: 35535204      PMCID: PMC9077106     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  34 in total

Review 1.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.

Authors:  Theresa L Whiteside
Journal:  Semin Cancer Biol       Date:  2005-09-08       Impact factor: 15.707

Review 2.  Review article: immune suppression and colorectal cancer.

Authors:  C Evans; A G Dalgleish; D Kumar
Journal:  Aliment Pharmacol Ther       Date:  2006-10-15       Impact factor: 8.171

3.  World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015.

Authors:  Shelley McGuire
Journal:  Adv Nutr       Date:  2016-03-15       Impact factor: 8.701

4.  Pyroptosis heats tumour immunity.

Authors:  Kirsty Minton
Journal:  Nat Rev Immunol       Date:  2020-05       Impact factor: 53.106

5.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

6.  Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer.

Authors:  H Nakayama; J Kitayama; T Muto; H Nagawa
Journal:  Jpn J Clin Oncol       Date:  2000-07       Impact factor: 3.019

7.  Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.

Authors:  S Ades; S Kumar; M Alam; A Goodwin; D Weckstein; M Dugan; T Ashikaga; M Evans; C Verschraegen; C E Holmes
Journal:  J Thromb Haemost       Date:  2015-04-23       Impact factor: 5.824

Review 8.  Pyroptosis: host cell death and inflammation.

Authors:  Tessa Bergsbaken; Susan L Fink; Brad T Cookson
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

Review 9.  Pyroptosis: A new frontier in cancer.

Authors:  Yuan Fang; Shengwang Tian; Yutian Pan; Wei Li; Qiming Wang; Yu Tang; Tao Yu; Xi Wu; Yongkang Shi; Pei Ma; Yongqian Shu
Journal:  Biomed Pharmacother       Date:  2019-11-09       Impact factor: 6.529

10.  Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.

Authors:  A G Heriot; J B Marriott; S Cookson; D Kumar; A G Dalgleish
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.